Law360, New York (December 02, 2010, 7:52 PM ET) -- AstraZeneca Pharmaceuticals Inc. has launched its second patent infringement suit against Mylan Pharmaceuticals Inc. in response to the generic-drug maker's most recent bid for regulatory approval to manufacture a copycat version of schizophrenia treatment Seroquel XR.
The drugmaker claims in the suit lodged Monday in the U.S. District Court for the Northern District of West Virginia that Mylan infringed U.S. Patent Numbers 4,879,288 and 5,948,437 through its submission of an abbreviated new drug application for permission to manufacture a 200 mg strength version of generic Seroquel...
AstraZeneca Seeks To Halt Mylan's 2nd Seroquel ANDA
To view the full article, take a free trial now.
